Back to results
US 2017/0304440 A1Published application
Treatment Methods for Rheumatoid Arthritis
OwnerL. Douglas GRAHAMinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis.
Claims29
A method for treating a patient with rheumatoid arthritis, wherein the method comprises:
- i. Determining serum levels in the patient of at least two biomarkers selected from the group consisting of Vascular Cell Adhesion Molecule 1, Vascular Endothelial Growth Factor-A, Interleukin-6, Tumor Necrosis Factor Receptor Type 1, Matrix Metalloproteinase-1, Matrix Metalloproteinase-3, YKL-40, Leptin, Resistin, Serum Amyloid A, and C-Reactive Protein;
- ii. Identifying at least two biomarkers each one with at least 40% elevated serum level over control serum level;
- iii. Selecting at least one treatment method that is known to affect the at least two biomarkers identified in step (ii), wherein the treatment method is selected from the group consisting of Plaquenil (or Hydroxychloroquine), Sulfasalazine, Methotrexate, Arava (or Leflunomide), Tumor Necrosis Factor-α inhibitors, Atabacept (or Orencia), Tocilizumab (or Actemra), Rituxan, and Tofacitinib (or Xeljanz);
- and
- iv. Administering the treatment selected in step (iii) to the patient.
2 more elements
A method for treating a patient with rheumatoid arthritis, wherein the method comprises:
- i. Determining serum levels in the patient of at least two biomarkers selected from the group consisting of Vascular Cell Adhesion Molecule 1, Vascular Endothelial Growth Factor-A, Interleukin-6, Tumor Necrosis Factor Receptor Type 1, Matrix Metalloproteinase-1, Matrix Metalloproteinase-3, YKL-40, Leptin, Resistin, Serum Amyloid A, and C-Reactive Protein;
- ii. Identifying at least two biomarkers each one with at least 40% elevated serum level over control serum level;
- iii. Selecting a first treatment method that is known to affect the at least two biomarkers identified in step (ii), wherein the treatment method is selected from the group consisting of Plaquenil (or Hydroxychloroquine), Sulfasalazine, Methotrexate, Arava (or Leflunomide), Tumor Necrosis Factor-α inhibitors, Atabacept (or Orencia), Tocilizumab (or Actemra), Rituxan, and Tofacitinib (or Xeljanz);
- and
- iv. Administering the first treatment method selected in step (iii) to the patient;
- and
- v. Determining effectiveness or ineffectiveness of the first treatment method administered in step (iv) to the patient.
4 more elements
Dependencies are inferred from the claim text.